On the other hand, it has been reported that in the group, a decrease in testosterone due to antiandrogen therapy including GnRH agonist administration in patients with prostate cancer and changes in body composition such as decreased muscle mass and increased fat mass were observed (27). This evidence concerns the gene GNRH1 and prostate carcinoma.